(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $5.29
发出时间: 15 Feb 2024 @ 03:56
回报率: -21.36%
上一信号: Feb 14 - 04:19
上一信号:
回报率: 1.15 %
Live Chart Being Loaded With Signals
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States...
Stats | |
---|---|
今日成交量 | 79 222.00 |
平均成交量 | 180 790 |
市值 | 54.03M |
EPS | $0 ( 2024-04-07 ) |
下一个收益日期 | ( $0 ) 2024-06-27 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 4.89 |
ATR14 | $0.0100 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Tarriff Scott | Sell | 2 119 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Buy | 3 800 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Sell | 1 589 | Common Stock |
2024-02-27 | Tarriff Scott | Buy | 12 950 | Common Stock |
2024-02-27 | Tarriff Scott | Sell | 3 154 | Common Stock |
INSIDER POWER |
---|
59.28 |
Last 99 transactions |
Buy: 818 589 | Sell: 362 958 |
音量 相关性
Eagle Pharmaceuticals Inc 相关性 - 货币/商品
Eagle Pharmaceuticals Inc 财务报表
Annual | 2022 |
营收: | $316.61M |
毛利润: | $221.67M (70.01 %) |
EPS: | $2.76 |
FY | 2022 |
营收: | $316.61M |
毛利润: | $221.67M (70.01 %) |
EPS: | $2.76 |
FY | 2021 |
营收: | $171.55M |
毛利润: | $129.37M (75.41 %) |
EPS: | $-0.0359 |
FY | 2020 |
营收: | $187.80M |
毛利润: | $142.34M (75.79 %) |
EPS: | $0.890 |
Financial Reports:
No articles found.
Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。